StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $11.45 | $12.15 | +6.11% | 0.3M |
| 05-14 | $12.22 | $11.98 | -1.96% | 0.2M |
| 05-15 | $11.93 | $11.03 | -7.54% | 0.2M |
| 05-18 | $11.06 | $9.95 | -10.04% | 0.2M |
| 05-19 | $9.79 | $9.64 | -1.53% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q1 2022 2022-03-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $881.71K |
Operating Income | $-39.84M | $-29.04M | $-8.52M | $-55.99M |
Net Income | $-42.35M | $-31.47M | $-9.44M | $-45.64M |
EPS (Diluted) | $-10.15 | $-7.55 | $-2.26 | $-11.15 |
Total Assets | $66.31M | $73.83M | $95.68M | $107.73M |
Total Liabilities | $33.32M | $31.88M | $34.52M | $38.62M |
Cash & Equivalents | $17.00M | $12.44M | $57.03M | $25.01M |
Free Cash Flow OCF − CapEx | $-37.56M | $-30.10M | $-10.63M | $-48.24M |
Shares Outstanding | 4.17M | 125.28M | 125.26M | 4.17M |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.